Regeneron Pharmaceuticals Inc. buy Truist Financial Co.
Summary
This prediction is currently active. With a performance of 35.34% the BUY prediction by Truist_Financial_Co_ is a big success. This prediction currently runs until 16.08.24. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | 1.554% | 1.554% |
iShares Core DAX® | 1.280% | 1.320% |
iShares Nasdaq 100 | -2.457% | -5.192% |
iShares Nikkei 225® | -2.006% | -1.389% |
iShares S&P 500 | -0.662% | -1.884% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Truist_Financial_Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
03.04.24
03.04.25
26.07.24
Regeneron Pharmaceuticals Inc.
26.03.24
26.03.25
26.07.24
Regeneron Pharmaceuticals Inc.
18.12.23
18.12.24
26.07.24
Regeneron Pharmaceuticals Inc.
28.11.23
28.11.24
26.07.24